MX2021006955A - Proceso para la preparacion de n-(3-azabiciclo[3.2.1]octan-8-il)ca rbamato de exo-terc-butilo. - Google Patents

Proceso para la preparacion de n-(3-azabiciclo[3.2.1]octan-8-il)ca rbamato de exo-terc-butilo.

Info

Publication number
MX2021006955A
MX2021006955A MX2021006955A MX2021006955A MX2021006955A MX 2021006955 A MX2021006955 A MX 2021006955A MX 2021006955 A MX2021006955 A MX 2021006955A MX 2021006955 A MX2021006955 A MX 2021006955A MX 2021006955 A MX2021006955 A MX 2021006955A
Authority
MX
Mexico
Prior art keywords
preparation
octan
azabicyclo
exo
carbamate
Prior art date
Application number
MX2021006955A
Other languages
English (en)
Inventor
Guocai Zhang
Weichun Chen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2021006955A publication Critical patent/MX2021006955A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención se refiere a un proceso para la preparación de un compuesto (I), o la sal farmacéuticamente aceptable del mismo, que es útil como el intermediario clave para la síntesis de compuestos para la profilaxis y el tratamiento de una enfermedad asociada con el depósito de amiloide-ß en el cerebro, en particular la enfermedad de Alzheimer, y otras enfermedades tales como la angiopatía amiloide cerebral, la hemorragia cerebral con amiloidosis hereditaria, de tipo Dutch (HCHWA-D), la demencia multiinfarto, la demencia pugilística y el síndrome de Down.
MX2021006955A 2018-12-27 2019-12-24 Proceso para la preparacion de n-(3-azabiciclo[3.2.1]octan-8-il)ca rbamato de exo-terc-butilo. MX2021006955A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018124296 2018-12-27
CN2019093185 2019-06-27
PCT/EP2019/087000 WO2020136188A1 (en) 2018-12-27 2019-12-24 Process for the preparation exo-tert-butyl n-(3-azabicyclo[3.2.1]octan-8-yl)carbamate

Publications (1)

Publication Number Publication Date
MX2021006955A true MX2021006955A (es) 2021-07-15

Family

ID=69159752

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006955A MX2021006955A (es) 2018-12-27 2019-12-24 Proceso para la preparacion de n-(3-azabiciclo[3.2.1]octan-8-il)ca rbamato de exo-terc-butilo.

Country Status (12)

Country Link
US (1) US20220073469A1 (es)
EP (1) EP3902779B1 (es)
JP (1) JP2022515610A (es)
KR (1) KR20210110309A (es)
CN (1) CN113165992A (es)
AU (1) AU2019412747A1 (es)
CA (1) CA3112418A1 (es)
ES (1) ES2940185T3 (es)
IL (1) IL283994B2 (es)
MX (1) MX2021006955A (es)
PL (1) PL3902779T3 (es)
WO (1) WO2020136188A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3199042A1 (en) 2020-12-11 2022-06-16 F. Hoffmann-La Roche Ag Process for the preparation of (9s)-n-[3-(6-methylpyrimidin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-9-(2,3,4-trifluorophenyl)-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[1,5-a]azepin-2-amine and its solid form

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227684B1 (en) * 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
CN103570621B (zh) * 2013-05-17 2015-04-29 万邦德制药集团股份有限公司 一种（-）-石杉碱甲的制备
WO2018118838A1 (en) 2016-12-20 2018-06-28 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease

Also Published As

Publication number Publication date
JP2022515610A (ja) 2022-02-21
WO2020136188A1 (en) 2020-07-02
ES2940185T3 (es) 2023-05-04
PL3902779T3 (pl) 2023-05-15
CA3112418A1 (en) 2020-07-02
AU2019412747A1 (en) 2021-04-08
KR20210110309A (ko) 2021-09-07
EP3902779B1 (en) 2023-01-18
CN113165992A (zh) 2021-07-23
IL283994B2 (en) 2024-05-01
IL283994A (en) 2021-07-29
TW202039441A (zh) 2020-11-01
US20220073469A1 (en) 2022-03-10
EP3902779A1 (en) 2021-11-03
IL283994B1 (en) 2024-01-01

Similar Documents

Publication Publication Date Title
ECSP21000990A (es) Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2)
MX2020001776A (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
MX2020011501A (es) Compuestos novedosos.
MX2017013483A (es) Compuestos y su uso como inhibidores de ?-secretasa 1 (bace1).
MY167264A (en) Bridged piperidine derivatives
HRP20160415T1 (hr) Inhibitori beta-sekretaze
TW201129562A (en) Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
JP2015511958A5 (es)
CY1118107T1 (el) Παραγωγα ετεροαρυλιου ως διαμορφωτες αλφα7 nachr
WO2014147021A3 (en) 3-acetylamino-1-(phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino)benzene derivatives for the treatment of hyperproliferative disorders
TW200734311A (en) New compounds
AR042423A1 (es) Diaril eteres como antagonistas del receptor opioide
UY30411A1 (es) Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
WO2006026204A3 (en) Novel gamma-lactams as beta-secretase inhibitors
AR110001A1 (es) Derivados heteroarilo bicíclicos
ECSP14013221A (es) Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento.
IN2014MN01756A (es)
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
MX2021006955A (es) Proceso para la preparacion de n-(3-azabiciclo[3.2.1]octan-8-il)ca rbamato de exo-terc-butilo.
MX2021015942A (es) Composiciones y métodos para tratar trastornos del snc.
WO2006082409A3 (en) Tricyclic cytoprotective compounds
CO2019007670A2 (es) Un derivado de oxazina base libre en forma cristalina
EP4296670A3 (en) Sulfopropanoic acid derivatives for treating neurodegenerative disorders
AR124195A1 (es) Proceso para la preparación 4-(3,5-difluorofenil)-n-[3-(6-metilpirimidin-4-il)-3-azabiciclo[3.2.1]octan-8-il]-6,7-dihidro-5h-[1,2,4]triazalo[1,5-a]pririmidin-2-amina
CO2021006837A2 (es) Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b][1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer